

National Institute for Health and Clinical Excellence

**Malignant Melanoma
Stakeholder Comments – Draft scope**

Please enter the name of your registered stakeholder organisation below.

NICE is unable to accept comments from non-registered organisation or individuals. If you wish your comments to be considered please register via the [NICE website](#) or contact the registered stakeholder organisation that most closely represents your interests and pass your comments to them.

Stakeholder organisation:	British Association of Dermatologists
----------------------------------	--

Name of commentator:	Dr Jenny Hughes, Consultant Dermatologist and Chair, Therapy & Guidelines sub-committee
-----------------------------	--

Comment No.	Section number <small>Indicate number or 'general' if your comment relates to the whole document</small>	Comments
		Please insert each new comment in a new row. Please do not paste other tables into this table, as your comments could get lost . type directly into this table

Example	3.4.6	Our comments are as follows ÷ ÷ ÷ .
----------------	--------------	--

Proformas that are not correctly submitted as detailed in the line above may be returned to you

1	4.1.1	The scoping document excludes mucosal (and ocular) melanoma, but includes penile and vulval melanoma. Whilst small numbers may be involved there may be vulval/penile melanomas which are mucosal and the scoping document wording should be changed to avoid confusion.
2	5	The scoping document mentions related NICE documents, including the %Skin Tumours including melanoma. NICE cancer service guidance (2010)+document . that document is the update for BCCs and does not mention melanomas. The relevant document is %OG Skin cancers including melanomas 2006+. The scoping document states that the final guidance will not replace or incorporate other existing NICE guidance, but inevitably it will replace the melanoma section of the 'IOG Skin cancers including melanomas 2006' guidance by being more recent and more focussed on melanoma and this should be acknowledged.
3	General	We propose melanoma <i>in situ</i> should be included.
4	General	Efforts should be made to ensure the guideline covers as much of the patient journey as possible and looks at the vision of integrated services available nationally.
5	General	Overall, we felt this to be a good and thorough scoping document with most of the pertinent issues covered.
6		
7		
8		
9		
10		
11		
12		

13		
14		
15		

Please add extra rows as needed

Please email this form to: malignantmelanoma@nice.org.uk

Closing date: 5pm on 1 February 2013

PLEASE NOTE: The Institute reserves the right to summarise and edit comments received during consultations, or not to publish them at all, where in the reasonable opinion of the Institute, the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.